Is West Pharmaceutical Services, Inc. overvalued or undervalued?

As of 30 April 2025, the valuation grade for West Pharmaceutical Services, Inc. has moved from expensive to fair. The company appears to be fairly valued at this time. Key ratios include a P/E ratio of 33, an EV to EBITDA of 21.43, and a return on equity (ROE) of 18.49%.
In comparison to peers, West's P/E ratio is lower than Intuitive Surgical, Inc. at 73.45 and Stryker Corp. at 33.20, while it is higher than Medtronic Plc, which has a P/E of 20.86. The company's recent stock performance has lagged behind the S&P 500, with a year-to-date return of -33.84% compared to the S&P 500's 2.44%, reinforcing the notion that the stock may be undervalued relative to its historical performance.